Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sulforafan alfadex - Evgen

Drug Profile

Sulforafan alfadex - Evgen

Alternative Names: Broccoli-sprout-extract; SFX-01; Stabilised sulforaphane; Sulforadex; Sulforafan-alpha-cyclodextrin; Sulforaphane; Sulforaphane-alpha-cyclodextrin; Sulphoraphane-alfadex

Latest Information Update: 06 Nov 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lalilab
  • Developer Evgen Pharma
  • Class Antihaemorrhagics; Antineoplastics; Chemopreventatives; Phytotherapies
  • Mechanism of Action Androgen receptor antagonists; Hedgehog protein modulators; Histone deacetylase inhibitors; NF E2 related factor 2 stimulants; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III SARS-CoV-2 acute respiratory disease
  • Phase II Breast cancer; Subarachnoid haemorrhage
  • No development reported Cardiovascular disorders; Chronic obstructive pulmonary disease; Leukaemia; Multiple sclerosis

Most Recent Events

  • 28 Oct 2020 No recent reports of development identified for preclinical development in Multiple-sclerosis in United Kingdom (PO)
  • 08 Oct 2020 Phase-II/III clinical trials in SARS-COV-2 acute respiratory disease (In adults, In the elderly) in United Kingdom (PO, Capsule) (EudraCT2020-003486-19)
  • 17 Jun 2020 Evgen Pharma plans a phase II/III trial in Acute respiratory distress syndrome associated with COVID-19 in United Kingdom (PO) in July 2020 (EudraCT2020-003486-19)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top